Search hospitals

>

Michigan

>

Wyoming

Metro Health Hospital

Claim this profile

Wyoming, Michigan 49519

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Cancer

311 reported clinical trials

4 medical researchers

Photo of Metro Health Hospital in WyomingPhoto of Metro Health Hospital in WyomingPhoto of Metro Health Hospital in Wyoming

Summary

Metro Health Hospital is a medical facility located in Wyoming, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Metro Health Hospital is involved with conducting 311 clinical trials across 439 conditions. There are 4 research doctors associated with this hospital, such as Kathleen J. Yost, Augusto Elias, MD, Fazeel Siddiqui, and Stephanie Dublis, DO.

Area of expertise

1

Breast Cancer

Global Leader

Metro Health Hospital has run 66 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV
2

Lung Cancer

Global Leader

Metro Health Hospital has run 50 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Metro Health Hospital

Breast Cancer

Lung Cancer

Breast cancer

Bladder Cancer

Melanoma

Ovarian Cancer

Colorectal Cancer

Pancreatic Cancer

Multiple Myeloma

Non-Small Cell Lung Cancer

Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Recruiting

2 awards

Phase 3

13 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Metro Health Hospital?

Where is Metro Health Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Metro Health Hospital accept?

What awards or recognition has Metro Health Hospital received?